Article(id=1326651797835461227, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1326651677442159392, articleNumber=null, orderNo=null, doi=10.13683/j.wph.2025.12.015, pmid=null, cstr=null, oa=null, hot=null, price=null, onlineType=0, articleFormat=0, articleType=null, articleTypeStr=null, receivedDate=1751644800000, receivedDateStr=2025-07-05, revisedDate=null, revisedDateStr=null, acceptedDate=null, acceptedDateStr=null, onlineDate=1794228036601, onlineDateStr=2026-11-09, pubDate=1765296000000, pubDateStr=2025-12-10, doiRegisterDate=null, doiRegisterDateStr=null, onlineIssueDate=1794228036601, onlineIssueDateStr=2026-11-09, onlineJustAcceptDate=null, onlineJustAcceptDateStr=null, onlineFirstDate=null, onlineFirstDateStr=null, sourceXml=null, magXml=null, createTime=1794228036601, creator=13701087609, updateTime=1794228036601, updator=13701087609, issue=Issue{id=1326651677442159392, tenantId=1146029695717560320, journalId=1319690329412173987, year='2025', volume='46', issue='12', pageStart='1201', pageEnd='1311', issueExtLink='null', onlineDate='null', pubDate='1765296000000', pubDateStr='2025-12-10', beforeIssueId=null, nextIssueId=null, price=null, status=1, issueComplete=1, articleOrder=1, issueType=-1, specialIssue=null, createTime=1794228007890, creator='13701087609', updateTime=1794272794012, updator='13701087609', preIssue=null, nextIssue=null, articleTotal=null, ext={EN=IssueExt(id=1326839524379964187, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1326651677442159392, language=EN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=), CN=IssueExt(id=1326839524379964188, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1326651677442159392, language=CN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=)}, issueFiles=null, downloadFileDto=null}, startPage=1298, endPage=1306, ext={EN=ArticleExt(id=1326651799630623342, articleId=1326651797835461227, tenantId=1146029695717560320, journalId=1319690329412173987, language=EN, title=Progress on nasal administration formulations of peptide drugs, columnId=1325221194584162830, journalTitle=World Clinical Drug, columnName=Review, runingTitle=null, highlight=null, articleAbstract=

Peptide drugs, with their high activity, low dosage, few adverse reactions and strong specificity, have shown broad application prospects and potential. However, oral administration is easily destroyed and poorly absorbed. The conventional administration route of peptide drugs is injection, which has poor patient compliance. Nasal administration of peptide drugs can overcome the problems of low bioavailability of oral administration and poor compliance of injection administration, and provide a potential brain-targeted delivery route for some drugs(such as insulin). This article systematically reviewed the marketed nasal peptide preparations and analyzed their advantages in terms of administration convenience and patient compliance compared with injection dosage forms. At the same time, it reviewed the peptide nasal preparations in clinical and preclinical research and discussed strategies to improve the delivery efficiency of peptide drugs.

, authors=Yanping JIANG, Wenzhe WU*, authorsList=Yanping JIANG, Wenzhe WU, authorCompany=null, correspAuthors=Wenzhe WU, authorNote=null, correspAuthorsNote=null, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=null, magXml=null, pdfUrl=null, pdf=null, pdfFileSize=null, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=null, mapNumber=null, fund=null), CN=ArticleExt(id=1326651800066830959, articleId=1326651797835461227, tenantId=1146029695717560320, journalId=1319690329412173987, language=CN, title=多肽类药物经鼻递送的研究进展, columnId=1325221194743546384, journalTitle=世界临床药物, columnName=综述评论, runingTitle=null, highlight=null, articleAbstract=

多肽类药物以其高活性、低剂量、不良反应少和特异性强的特点,展现出广阔的应用前景和潜力,其口服给药易被破坏,吸收不佳;常规给药途径为注射给药,但患者用药顺应性较差。多肽类药物经鼻给药能克服口服给药生物利用度低以及注射给药的顺应性差等问题,并为部分药物(如胰岛素)提供潜在的脑靶向递送途径。该文系统梳理已上市的鼻用多肽制剂,分析其相较于注射剂型在给药便捷性和患者顺应性方面的优势;同时,综述处于临床及临床前研究的多肽鼻用制剂,并探讨提升多肽类药物递送效率的策略。

, authors=姜艳平, 吴闻哲*, authorsList=姜艳平, 吴闻哲, authorCompany=null, correspAuthors=吴闻哲, authorNote=

姜艳平,硕士研究生,研究方向:肺部吸入给药。

, correspAuthorsNote=
吴闻哲,研究员,硕士生导师,从事经鼻及吸入给药研究。
, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=m11ocTwW0ddwtz5Ecu4paQ==, magXml=J4POLw30wvNBcp7MEBk7CA==, pdfUrl=null, pdf=jUNTaVa7yFYPMfDsu+whdg==, pdfFileSize=1832520, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=JRG3bi9zHgtY7Xh26bBDGg==, mapNumber=null, fund=null)}, authors=[Author(id=1326651800364626548, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651797835461227, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1326651800440124022, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651797835461227, authorId=1326651800364626548, language=EN, stringName=Yanping JIANG, firstName=Yanping, middleName=null, lastName=JIANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=National Advanced Medical Engineering Research Center, China State Institute of Pharmaceutical Industry, Shanghai 201203, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1326651800536593015, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651797835461227, authorId=1326651800364626548, language=CN, stringName=姜艳平, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=中国医药工业研究总院医药先进制造国家工程研究中心,上海 201203, bio={"content":"

姜艳平,硕士研究生,研究方向:肺部吸入给药。

"}, bioImg=null, bioContent=

姜艳平,硕士研究生,研究方向:肺部吸入给药。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1326651800272351856, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651797835461227, xref=null, ext=[AuthorCompanyExt(id=1326651800280740465, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651797835461227, companyId=1326651800272351856, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=National Advanced Medical Engineering Research Center, China State Institute of Pharmaceutical Industry, Shanghai 201203, China), AuthorCompanyExt(id=1326651800289129074, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651797835461227, companyId=1326651800272351856, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=中国医药工业研究总院医药先进制造国家工程研究中心,上海 201203)])]), Author(id=1326651800612090489, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651797835461227, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1326651800763085435, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651797835461227, authorId=1326651800612090489, language=EN, stringName=Wenzhe WU, firstName=Wenzhe, middleName=null, lastName=WU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=*, address=National Advanced Medical Engineering Research Center, China State Institute of Pharmaceutical Industry, Shanghai 201203, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1326651800893108860, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651797835461227, authorId=1326651800612090489, language=CN, stringName=吴闻哲, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=*, address=中国医药工业研究总院医药先进制造国家工程研究中心,上海 201203, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1326651800272351856, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651797835461227, xref=null, ext=[AuthorCompanyExt(id=1326651800280740465, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651797835461227, companyId=1326651800272351856, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=National Advanced Medical Engineering Research Center, China State Institute of Pharmaceutical Industry, Shanghai 201203, China), AuthorCompanyExt(id=1326651800289129074, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651797835461227, companyId=1326651800272351856, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=中国医药工业研究总院医药先进制造国家工程研究中心,上海 201203)])])], keywords=[Keyword(id=1326651801002160765, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651797835461227, language=EN, orderNo=1, keyword=peptide drug), Keyword(id=1326651801090241150, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651797835461227, language=EN, orderNo=2, keyword=nasal administration), Keyword(id=1326651801153155711, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651797835461227, language=EN, orderNo=3, keyword=marketed situation), Keyword(id=1326651801241236096, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651797835461227, language=EN, orderNo=4, keyword=clinical research), Keyword(id=1326651801325122177, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651797835461227, language=EN, orderNo=5, keyword=delivery efficiency), Keyword(id=1326651801413202562, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651797835461227, language=CN, orderNo=1, keyword=多肽类药物), Keyword(id=1326651801501282947, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651797835461227, language=CN, orderNo=2, keyword=经鼻给药), Keyword(id=1326651801568391812, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651797835461227, language=CN, orderNo=3, keyword=上市情况), Keyword(id=1326651801652277893, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651797835461227, language=CN, orderNo=4, keyword=临床研究), Keyword(id=1326651801723581062, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651797835461227, language=CN, orderNo=5, keyword=递送效率)], refs=[Reference(id=1326651801820050055, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651797835461227, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[1], rfOrder=0, authorNames=null, journalName=null, refType=null, unstructuredReference=MUTTENTHALER M, KING GF, ADAMS DJ, et al. Trends in peptide drug discovery[J]. Nat Rev Drug Discov, 2021,20(4): 309-325., articleTitle=null, refAbstract=null), Reference(id=1326651801908130440, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651797835461227, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[2], rfOrder=1, authorNames=null, journalName=null, refType=null, unstructuredReference=FORBES J, KRISHNAMURTHY K. Biochemistry,peptide[M]. Treasure Island: StatPearls, 2024., articleTitle=null, refAbstract=null), Reference(id=1326651802017182345, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651797835461227, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[3], rfOrder=2, authorNames=null, journalName=null, refType=null, unstructuredReference=MYSKOVA A, SYKORA D, KUNES J, et al. Lipidization as a tool toward peptide therapeutics[J]. Drug Deliv, 2023,30(1): 2284685., articleTitle=null, refAbstract=null), Reference(id=1326651802105262730, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651797835461227, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[4], rfOrder=3, authorNames=null, journalName=null, refType=null, unstructuredReference=胡筱芸, 岳霄, 吴传斌, 等. 鼻腔药物递送的影响因素和提高递送效率的设计策略[J]. 浙江大学学报(医学版), 2023,52(3): 328-337., articleTitle=null, refAbstract=null), Reference(id=1326651802201731723, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651797835461227, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[5], rfOrder=4, authorNames=null, journalName=null, refType=null, unstructuredReference=LAFFLEUR F, BAUER B. Progress in nasal drug delivery systems[J]. Int J Pharm, 2021, 607: 120994., articleTitle=null, refAbstract=null), Reference(id=1326651803875259022, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651797835461227, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[6], rfOrder=5, authorNames=null, journalName=null, refType=null, unstructuredReference=Food and Drug Administration. DDAVP(desmopressin-acetate) nasal spray[EB/OL]. (2018-10-22)[2024-08-22].https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/017922s046lbl.pdf., articleTitle=null, refAbstract=null), Reference(id=1326651803984310927, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651797835461227, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[7], rfOrder=6, authorNames=null, journalName=null, refType=null, unstructuredReference=JOUKHADAR C, SCHENK B, KAEHLER ST, et al. A replicate study design for testing bioequivalence: a case study on two desmopressin nasal spray preparations[J]. Eur J Clin Pharmacol, 2003, 59(8-9): 631-636., articleTitle=null, refAbstract=null), Reference(id=1326651804068197008, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651797835461227, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[8], rfOrder=7, authorNames=null, journalName=null, refType=null, unstructuredReference=FEIN S. Safe desmopressin administration: US,11419914B2[P]. 2022-08-23., articleTitle=null, refAbstract=null), Reference(id=1326651804185637521, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651797835461227, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[9], rfOrder=8, authorNames=null, journalName=null, refType=null, unstructuredReference=ANDERSSON KE, LONGSTRETH J, BRUCKER BM, et al. Pharmacokinetic and pharmacodynamic properties of a micro-dose nasal spray formulation of desmopressin(AV002)in healthy water-loaded subjects[J]. Pharm Res, 2019, 36(6):92., articleTitle=null, refAbstract=null), Reference(id=1326651804269523602, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651797835461227, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[10], rfOrder=9, authorNames=null, journalName=null, refType=null, unstructuredReference=FRANSEN N, BREDENBERG S, BJORK E. Clinical study shows improved absorption of desmopressin with novel formulation[J]. Pharm Res, 2009, 26(7): 1618-1625., articleTitle=null, refAbstract=null), Reference(id=1326651804345021075, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651797835461227, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[11], rfOrder=10, authorNames=null, journalName=null, refType=null, unstructuredReference=FAKHR MS, KARIMI F, REZVANFAR K, et al. Comparison of the effects of vitamin D and nasal calcitonin spray with nasal calcitonin spray on postoperative abdominal pain: a randomised controlled trial[J]. Int J Surg Open, 2023, 59:100687., articleTitle=null, refAbstract=null), Reference(id=1326651804412129940, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651797835461227, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[12], rfOrder=11, authorNames=null, journalName=null, refType=null, unstructuredReference=HOYER H, PERERA G, BERNKOP-SCHNURCH A.Noninvasive delivery systems for peptides and proteins in osteoporosis therapy: a retroperspective[J]. Drug Dev Ind Pharm, 2010, 36(1): 31-44., articleTitle=null, refAbstract=null), Reference(id=1326651804479238805, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651797835461227, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[13], rfOrder=12, authorNames=null, journalName=null, refType=null, unstructuredReference=KANIS JA, BURLET N, COOPER C, et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women[J]. Osteoporos Int, 2008, 19(4):399-428., articleTitle=null, refAbstract=null), Reference(id=1326651804554736278, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651797835461227, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[14], rfOrder=13, authorNames=null, journalName=null, refType=null, unstructuredReference=SANDOVAL DA, D'ALESSIO DA. Physiology of proglucagon peptides: role of glucagon and GLP-1 in health and disease[J]. Physiol Rev, 2015, 95(2): 513-548., articleTitle=null, refAbstract=null), Reference(id=1326651804667982487, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651797835461227, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[15], rfOrder=14, authorNames=null, journalName=null, refType=null, unstructuredReference=KUMAR S, SANAP SN, PANDEY P, et al. Glucagon:Delivery advancements for hypoglycemia management[J].Int J Pharm, 2024, 652: 123785., articleTitle=null, refAbstract=null), Reference(id=1326651804768645784, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651797835461227, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[16], rfOrder=15, authorNames=null, journalName=null, refType=null, unstructuredReference=MANTRIPRAGADA S, PICHE C A, FILIP J J, et al. Nasal powder formulation for treatment of hypoglycemia: US,10213487B2[P]. 2019-02-26., articleTitle=null, refAbstract=null), Reference(id=1326651804856726169, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651797835461227, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[17], rfOrder=16, authorNames=null, journalName=null, refType=null, unstructuredReference=NGUYEN LH, JR WHITE JR. Nasal glucagon: a promising new way to treat severe hypoglycemia[J]. Clin Diabetes,2019, 37(3): 292-293., articleTitle=null, refAbstract=null), Reference(id=1326651804911252122, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651797835461227, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[18], rfOrder=17, authorNames=null, journalName=null, refType=null, unstructuredReference=GIMENEZ M, KHUNTI K, MATSUHISA M, et al.Systematic literature review and indirect treatment comparison of three ready-to-use glucagon treatments for severe hypoglycemia[J]. Diabetes Ther, 2023, 14(11): 1757-1769., articleTitle=null, refAbstract=null), Reference(id=1326651804974166683, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651797835461227, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[19], rfOrder=18, authorNames=null, journalName=null, refType=null, unstructuredReference=TANAKA A, FURUBAYASHI T, ARAI M, et al. Delivery of oxytocin to the brain for the treatment of autism spectrum disorder by nasal application[J]. Mol Pharm, 2018, 15(3):1105-1111., articleTitle=null, refAbstract=null), Reference(id=1326651805037081244, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651797835461227, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[20], rfOrder=19, authorNames=null, journalName=null, refType=null, unstructuredReference=BHARGAVA R, DAUGHTERS KL, REES A. Oxytocin therapy in hypopituitarism: challenges and opportunities[J].Clin Endocrinol(Oxf), 2019, 90(2): 257-264., articleTitle=null, refAbstract=null), Reference(id=1326651805099995805, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651797835461227, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[21], rfOrder=20, authorNames=null, journalName=null, refType=null, unstructuredReference=GOSSEN A, HAHN A, WESTPHAL L, et al. Oxytocin plasma concentrations after single intranasal oxytocin administration - a study in healthy men[J]. Neuropeptides,2012, 46(5): 211-215., articleTitle=null, refAbstract=null), Reference(id=1326651805183881886, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651797835461227, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[22], rfOrder=21, authorNames=null, journalName=null, refType=null, unstructuredReference=FORTUNA A, ALVES G, SERRALHEIRO A, et al.Intranasal delivery of systemic-acting drugs: small-molecules and biomacromolecules[J]. Eur J Pharm Biopharm, 2014,88(1): 8-27., articleTitle=null, refAbstract=null), Reference(id=1326651805246796447, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651797835461227, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[23], rfOrder=22, authorNames=null, journalName=null, refType=null, unstructuredReference=Health Canada. SUPREFACT® buserelin acetate[EB/OL]. (2020-06-02)[2024-08-22]. https://pdf.hres.ca/dpd_pm/00056627.PDF., articleTitle=null, refAbstract=null), Reference(id=1326651805309711008, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651797835461227, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[24], rfOrder=23, authorNames=null, journalName=null, refType=null, unstructuredReference=Food and Drug Administration. Synarel®(nafarelin acetate) nasal solution[EB/OL]. (2023-01-31)[2024-08-22]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/019886s039lbl.pdf., articleTitle=null, refAbstract=null), Reference(id=1326651805372625569, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651797835461227, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[25], rfOrder=24, authorNames=null, journalName=null, refType=null, unstructuredReference=BROGDEN RN, BUCKLEY MM, WARD A. Buserelin.A review of its pharmacodynamic and pharmacokinetic properties, and clinical profile[J]. Drugs, 1990, 39(3): 399-437., articleTitle=null, refAbstract=null), Reference(id=1326651805448123042, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651797835461227, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[26], rfOrder=25, authorNames=null, journalName=null, refType=null, unstructuredReference=FALKSON CI, FALKSON G, FALKSON HC. Long term follow-up of patients with advanced prostatic cancer treated with nasal buserelin[J]. Ann Oncol, 1991, 2(4): 303-304., articleTitle=null, refAbstract=null), Reference(id=1326651805515231907, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651797835461227, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[27], rfOrder=26, authorNames=null, journalName=null, refType=null, unstructuredReference=LEE D, MINKO T. Nanotherapeutics for nose-to-brain drug delivery: an approach to bypass the blood brain barrier[J].Pharmaceutics, 2021, 13(12): 2049., articleTitle=null, refAbstract=null), Reference(id=1326651805578146468, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651797835461227, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[28], rfOrder=27, authorNames=null, journalName=null, refType=null, unstructuredReference=PATHARAPANKAL EJ, AJIBOYE AL, MATTERN C, et al. Nose-to-brain(N2B) delivery: an alternative route for the delivery of biologics in the management and treatment of central nervous system disorders[J]. Pharmaceutics, 2023,16(1): 66., articleTitle=null, refAbstract=null), Reference(id=1326651805645255333, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651797835461227, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[29], rfOrder=28, authorNames=null, journalName=null, refType=null, unstructuredReference=马琳莎, 贾国舒, 周一萌, 等. 鼻用生物制品的进展与挑战[J]. 中国现代应用药学, 2023, 40(20): 2802-2810., articleTitle=null, refAbstract=null), Reference(id=1326651805729141414, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651797835461227, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[30], rfOrder=29, authorNames=null, journalName=null, refType=null, unstructuredReference=王晟蕾, 李凤珍, 李腾飞, 等. 胰岛素鼻腔给药治疗阿尔茨海默病研究进展[J]. 海军军医大学学报, 2024, 45(3): 333-339., articleTitle=null, refAbstract=null), Reference(id=1326651805792055975, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651797835461227, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[31], rfOrder=30, authorNames=null, journalName=null, refType=null, unstructuredReference=BENDICHO-LAVILLA C, SEOANE-VIANO I, OTERO-ESPINAR FJ, et al. Fighting type 2 diabetes: formulation strategies for peptide-based therapeutics[J]. Acta Pharm Sin B, 2022, 12(2): 621-636., articleTitle=null, refAbstract=null), Reference(id=1326651805859164840, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651797835461227, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[32], rfOrder=31, authorNames=null, journalName=null, refType=null, unstructuredReference=RABINOWICZ AL, CARRAZANA E, MAGGIO ET.Improvement of intranasal drug delivery with Intravail®alkylsaccharide excipient as a mucosal absorption enhancer aiding in the treatment of conditions of the central nervous system[J]. Drugs R D, 2021, 21(4): 361-369., articleTitle=null, refAbstract=null), Reference(id=1326651805926273705, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651797835461227, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[33], rfOrder=32, authorNames=null, journalName=null, refType=null, unstructuredReference=LOCHHEAD JJ, THORNE RG. Intranasal delivery of biologics to the central nervous system[J]. Adv Drug Deliv Rev, 2012, 64(7): 614-628., articleTitle=null, refAbstract=null), Reference(id=1326651806001771178, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651797835461227, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[34], rfOrder=33, authorNames=null, journalName=null, refType=null, unstructuredReference=NEDELCOVYCH MT, GADIANO AJ, WU Y, et al.Pharmacokinetics of intranasal versus subcutaneous insulin in the mouse[J]. ACS Chem Neurosci, 2018, 9(4): 809-816., articleTitle=null, refAbstract=null), Reference(id=1326651806060491435, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651797835461227, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[35], rfOrder=34, authorNames=null, journalName=null, refType=null, unstructuredReference=LI Y, HE J, LYU X, et al. Chitosan-based thermosensitive hydrogel for nasal delivery of exenatide: effect of magnesium chloride[J]. Int J Pharm, 2018, 553(1-2): 375-385., articleTitle=null, refAbstract=null), Reference(id=1326651806119211692, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651797835461227, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[36], rfOrder=35, authorNames=null, journalName=null, refType=null, unstructuredReference=MILEWSKI M, GOODEY A, LEE D, et al. Rapid absorption of dry-powder intranasal oxytocin[J]. Pharm Res, 2016,33(8): 1936-1944., articleTitle=null, refAbstract=null), Reference(id=1326651806173737645, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651797835461227, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[37], rfOrder=36, authorNames=null, journalName=null, refType=null, unstructuredReference=DAS A, VARTAK R, ISLAM MA, et al. Arginine-coated nanoglobules for the nasal delivery of insulin[J].Pharmaceutics, 2023, 15(2): 353., articleTitle=null, refAbstract=null), Reference(id=1326651806270206638, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651797835461227, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[38], rfOrder=37, authorNames=null, journalName=null, refType=null, unstructuredReference=GHADIRI M, YOUNG PM, TRAINI D. Strategies to enhance drug absorption via nasal and pulmonary routes[J].Pharmaceutics, 2019, 11(3):113., articleTitle=null, refAbstract=null), Reference(id=1326651806349898415, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651797835461227, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[39], rfOrder=38, authorNames=null, journalName=null, refType=null, unstructuredReference=MATSUYAMA T, MORITA T, HORIKIRI Y, et al.Enhancement of nasal absorption of large molecular weight compounds by combination of mucolytic agent and nonionic surfactant[J]. J Control Release, 2006, 110(2): 347-352., articleTitle=null, refAbstract=null), Reference(id=1326651806505087664, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651797835461227, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[40], rfOrder=39, authorNames=null, journalName=null, refType=null, unstructuredReference=WILLIAMS AJ, JORDAN F, KING G, et al. In vitro and preclinical assessment of an intranasal spray formulation of parathyroid hormone PTH 1-34 for the treatment of osteoporosis[J]. Int J Pharm, 2018, 535(1-2): 113-119., articleTitle=null, refAbstract=null), Reference(id=1326651806588973745, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651797835461227, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[41], rfOrder=40, authorNames=null, journalName=null, refType=null, unstructuredReference=方笑语, 葛渊源. FDA已批准鼻用制剂的辅料分析及研究进展[J]. 中国现代应用药学, 2023, 40(20): 2811-2817., articleTitle=null, refAbstract=null), Reference(id=1326651806651888306, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651797835461227, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[42], rfOrder=41, authorNames=null, journalName=null, refType=null, unstructuredReference=CALMET H, INTHAVONG K, EGUZKITZA B, et al. Nasal sprayed particle deposition in a human nasal cavity under different inhalation conditions[J]. PLoS One, 2019, 14(9):e0221330., articleTitle=null, refAbstract=null), Reference(id=1326651806802883251, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651797835461227, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[43], rfOrder=42, authorNames=null, journalName=null, refType=null, unstructuredReference=BOYUKLIEVA R, PILICHEVA B. Micro- and nanosized carriers for nose-to-brain drug delivery in neurodegenerative disorders[J]. Biomedicines, 2022, 10(7): 1706., articleTitle=null, refAbstract=null), Reference(id=1326651808409301686, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651797835461227, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[44], rfOrder=43, authorNames=null, journalName=null, refType=null, unstructuredReference=LAPIDOT T, BOUHAJIB M, FAULKNOR J, et al. A novel faster-acting, dry powder-based, naloxone intranasal formulation for opioid overdose[J]. Pharm Res, 2022,390(5): 963-975., articleTitle=null, refAbstract=null), Reference(id=1326651808543519415, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651797835461227, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[45], rfOrder=44, authorNames=null, journalName=null, refType=null, unstructuredReference=GAO M, SHEN X, MAO S. Factors influencing drug deposition in the nasal cavity upon delivery via nasal sprays[J]. J Pharm Invest, 2020, 50(3): 251-259., articleTitle=null, refAbstract=null), Reference(id=1326651808639988408, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651797835461227, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[46], rfOrder=45, authorNames=null, journalName=null, refType=null, unstructuredReference=TIOZZO FASIOLO L, MANNIELLO MD, TRATTA E,et al. Opportunity and challenges of nasal powders: Drug formulation and delivery[J]. Eur J Pharm Sci, 2018, 113:2-17., articleTitle=null, refAbstract=null), Reference(id=1326651808732263097, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651797835461227, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[47], rfOrder=46, authorNames=null, journalName=null, refType=null, unstructuredReference=DJUPESLAND PG. Nasal drug delivery devices:characteristics and performance in a clinical perspective - a review[J]. Drug Deliv Transl Res, 2013, 3(1): 42-62., articleTitle=null, refAbstract=null), Reference(id=1326651808811954874, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651797835461227, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[48], rfOrder=47, authorNames=null, journalName=null, refType=null, unstructuredReference=GANGER S, SCHINDOWSKI K. Tailoring formulations for intranasal nose-to-brain delivery: a review on architecture,physico-chemical characteristics and mucociliary clearance of the nasal olfactory mucosa[J]. Pharmaceutics, 2018, 10(3):116., articleTitle=null, refAbstract=null), Reference(id=1326651808883258043, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651797835461227, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[49], rfOrder=48, authorNames=null, journalName=null, refType=null, unstructuredReference=DESAI MM, PATIL PD, JADHAV SA, et al. Recent advancements in nasal drug delivery devices[J]. Int J Drug Deliv Technol, 2024, 14(4): 619-624., articleTitle=null, refAbstract=null)], funds=null, companyList=[AuthorCompany(id=1326651800272351856, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651797835461227, xref=null, ext=[AuthorCompanyExt(id=1326651800280740465, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651797835461227, companyId=1326651800272351856, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=National Advanced Medical Engineering Research Center, China State Institute of Pharmaceutical Industry, Shanghai 201203, China), AuthorCompanyExt(id=1326651800289129074, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651797835461227, companyId=1326651800272351856, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=中国医药工业研究总院医药先进制造国家工程研究中心,上海 201203)])], figs=null, attaches=null, journal=Journal(id=1319689997550452896, delFlag=0, nameCn=世界临床药物, nameEn=World Clinical Drug, nameHistory1=null, nameHistory2=null, issn=1672-9188, eissn=null, cn=31-1939/R, coden=SLYHAA, periodic=0, language=CN, oaType=null, ccby=null, superviseOffice=null, ownerOffice=null, pubOffice=null, editorOffice=null, officeType=null, aims=null, clcCode=null, officeProv=null, officeCity=null, officeAddr=null, officeZip=null, officeEmail=null, officePhone=null, editDirector=null, officeDirector=null, officeDirectorPhone=null, officeStaffNum=null, officeEmpNum=null, coverPicUrl=9c6IkcJKa1cF20h1u6lJeQ==, journalPrice=null, startedYear=null, abbrevIsoEn=World Clinical Drug, journalRemark=null, publicationField=null, createdTime=1792568214072, updatedTime=1792747519563, createdBy=18614031015, updatedBy=13701087609, firstLetterCn=S, firstLetterEn=S, subjectCode=Medical and Pharmaceutical Sciences, subjectName=null, subjectCodeEn=Medical and Pharmaceutical Sciences, subjectNameEn=null, picCn=9c6IkcJKa1cF20h1u6lJeQ==, picEn=MRqUlTwfL6oqIHNy7eyFZQ==, jcr=null, cjcr=null, exts=[JournalExt(id=1320442059660570919, language=CN, name=世界临床药物, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747519650, updatedTime=1792747519650, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=http://www.jwph.com.cn/journalx_sjlcyw/authorLogOn.action, submissionEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorLogOn.action, submissionReviewUrl=http://www.jwph.com.cn/journalx_sjlcyw/expertLogOn.action, submissionCeEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorInChiefLogOn.action, submissionAeEditorUrl=, option={"copyright":""}), JournalExt(id=1320442059723485480, language=EN, name=World Clinical Drug, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747519665, updatedTime=1792747519665, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=http://www.jwph.com.cn/journalx_sjlcyw/authorLogOn.action, submissionEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorLogOn.action, submissionReviewUrl=http://www.jwph.com.cn/journalx_sjlcyw/expertLogOn.action, submissionCeEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorInChiefLogOn.action, submissionAeEditorUrl=, option={"copyright":""})], databaseList=null, tenantJournalId=1319690329412173987, websiteList=[Website(id=1321427104911179915, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690329412173987, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/sjlcyw/CN, language=CN, createTime=1792982372739, createBy=18614031015, updateTime=1792982514949, updateBy=18614031015, name=世界临床药物-中文, tplId=1146099689490845704, title=世界临床药物, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428428256031726, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=articleTextType, value=kx, createTime=1792982688249, updateTime=1792982688249, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428193117163, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=banner, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic?fileId=RR/csUBcM48ejcuaaK5s0g==, createTime=1792982688234, updateTime=1792982688234, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428302169073, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=grayFlag, value=0, createTime=1792982688260, updateTime=1792982688260, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428172145642, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=logo, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic?fileId=yyY2emcxcV1CfIeK9tH8ZA==, createTime=1792982688229, updateTime=1792982688229, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428327334899, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=minRunFlag, value=0, createTime=1792982688266, updateTime=1792982688266, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428226671597, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic, createTime=1792982688242, updateTime=1792982688242, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428314751986, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=silenceFlag, value=0, createTime=1792982688263, updateTime=1792982688263, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428209894380, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_cn_619/, createTime=1792982688238, updateTime=1792982688238, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428268614639, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=themeColor, value=null, createTime=1792982688252, updateTime=1792982688252, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428289586160, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982688257, updateTime=1792982688257, creator=18614031015, updator=18614031015)]), Website(id=1321427104990871693, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690329412173987, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/sjlcyw/EN, language=EN, createTime=1792982372758, createBy=18614031015, updateTime=1792982556355, updateBy=18614031015, name=世界临床药物-英文, tplId=1146101810881728533, title=World Clinical Drug, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428446820021244, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=articleTextType, value=kx, createTime=1792982692675, updateTime=1792982692675, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446757106681, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=banner, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic?fileId=RR/csUBcM48ejcuaaK5s0g==, createTime=1792982692660, updateTime=1792982692660, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447109428223, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=grayFlag, value=0, createTime=1792982692744, updateTime=1792982692744, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446736135160, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=logo, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic?fileId=yyY2emcxcV1CfIeK9tH8ZA==, createTime=1792982692655, updateTime=1792982692655, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447142981632, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=minRunFlag, value=0, createTime=1792982692752, updateTime=1792982692752, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446790661115, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic, createTime=1792982692668, updateTime=1792982692668, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447130399745, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=silenceFlag, value=0, createTime=1792982692749, updateTime=1792982692749, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446769689594, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_en_623/, createTime=1792982692663, updateTime=1792982692663, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446832604157, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=themeColor, value=null, createTime=1792982692678, updateTime=1792982692678, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447092651006, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982692740, updateTime=1792982692740, creator=18614031015, updator=18614031015)])], journalTitle=世界临床药物, weixinUrl=null, journalUrl=http://www.jwph.com.cn/, iacademicId=null, status=1, seqNo=null, journalTitleEn=World Clinical Drug, journalPhotoCn=9c6IkcJKa1cF20h1u6lJeQ==, journalPhotoEn=MRqUlTwfL6oqIHNy7eyFZQ==, journalFirstLetter=S, journalRecommend=null, journalNew=null, journalCollection=null, jcrJf=null, cjcrJf=null, jcrJfStr=null, cjcrJfStr=null, submissionFirstDecision=null, sciSubjectClassification=null, casSubjectClassification=null, citeScore=null, totalCitationFrequency=null, icpCode=null, psCode=null, advertisingLicenseCode=null, copyrightInformation=null, country=null, option=, provinceCode=null, provinceName=null, collectFlag=false, interPubPlatform=, interPubPlatformUrl=null), detailUrlCn=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/10.13683/j.wph.2025.12.015, detailUrlEn=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2025.12.015, pdfUrlCn=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/PDF/10.13683/j.wph.2025.12.015, pdfUrlEn=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/PDF/10.13683/j.wph.2025.12.015, aliStartDate=0, aliEndDate=0, collectionFlag=false, citedCount=null, citedUrl=null, previewStatus=0, delFlag=0, hasFullText=0, orderTime=1765296000000, fullTextJson=null, articleText=null, reference=null)
收藏切换
多肽类药物经鼻递送的研究进展
姜艳平 , 吴闻哲 *
世界临床药物 | 综述评论 2025,46(12): 1298-1306
收起
收藏切换
世界临床药物 |综述评论 2025 , 46 (12) : 1298 -1306
多肽类药物经鼻递送的研究进展
全屏
[Author(id=1326651800364626548, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651797835461227, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1326651800440124022, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651797835461227, authorId=1326651800364626548, language=EN, stringName=Yanping JIANG, firstName=Yanping, middleName=null, lastName=JIANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=National Advanced Medical Engineering Research Center, China State Institute of Pharmaceutical Industry, Shanghai 201203, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1326651800536593015, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651797835461227, authorId=1326651800364626548, language=CN, stringName=姜艳平, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=中国医药工业研究总院医药先进制造国家工程研究中心,上海 201203, bio={"content":"

姜艳平,硕士研究生,研究方向:肺部吸入给药。

"}, bioImg=null, bioContent=

姜艳平,硕士研究生,研究方向:肺部吸入给药。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1326651800272351856, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651797835461227, xref=null, ext=[AuthorCompanyExt(id=1326651800280740465, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651797835461227, companyId=1326651800272351856, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=National Advanced Medical Engineering Research Center, China State Institute of Pharmaceutical Industry, Shanghai 201203, China), AuthorCompanyExt(id=1326651800289129074, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651797835461227, companyId=1326651800272351856, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=中国医药工业研究总院医药先进制造国家工程研究中心,上海 201203)])]), Author(id=1326651800612090489, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651797835461227, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1326651800763085435, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651797835461227, authorId=1326651800612090489, language=EN, stringName=Wenzhe WU, firstName=Wenzhe, middleName=null, lastName=WU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=*, address=National Advanced Medical Engineering Research Center, China State Institute of Pharmaceutical Industry, Shanghai 201203, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1326651800893108860, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651797835461227, authorId=1326651800612090489, language=CN, stringName=吴闻哲, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=*, address=中国医药工业研究总院医药先进制造国家工程研究中心,上海 201203, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1326651800272351856, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651797835461227, xref=null, ext=[AuthorCompanyExt(id=1326651800280740465, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651797835461227, companyId=1326651800272351856, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=National Advanced Medical Engineering Research Center, China State Institute of Pharmaceutical Industry, Shanghai 201203, China), AuthorCompanyExt(id=1326651800289129074, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326651797835461227, companyId=1326651800272351856, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=中国医药工业研究总院医药先进制造国家工程研究中心,上海 201203)])])]
姜艳平, 吴闻哲*
作者信息
  • 中国医药工业研究总院医药先进制造国家工程研究中心,上海 201203
通讯作者:
吴闻哲,研究员,硕士生导师,从事经鼻及吸入给药研究。
作者简介:

姜艳平,硕士研究生,研究方向:肺部吸入给药。

Progress on nasal administration formulations of peptide drugs
Yanping JIANG, Wenzhe WU*
Affiliations
  • National Advanced Medical Engineering Research Center, China State Institute of Pharmaceutical Industry, Shanghai 201203, China
出版时间: 2025-12-10 doi: 10.13683/j.wph.2025.12.015
文章导航
收藏切换

多肽类药物以其高活性、低剂量、不良反应少和特异性强的特点,展现出广阔的应用前景和潜力,其口服给药易被破坏,吸收不佳;常规给药途径为注射给药,但患者用药顺应性较差。多肽类药物经鼻给药能克服口服给药生物利用度低以及注射给药的顺应性差等问题,并为部分药物(如胰岛素)提供潜在的脑靶向递送途径。该文系统梳理已上市的鼻用多肽制剂,分析其相较于注射剂型在给药便捷性和患者顺应性方面的优势;同时,综述处于临床及临床前研究的多肽鼻用制剂,并探讨提升多肽类药物递送效率的策略。

多肽类药物  /  经鼻给药  /  上市情况  /  临床研究  /  递送效率

Peptide drugs, with their high activity, low dosage, few adverse reactions and strong specificity, have shown broad application prospects and potential. However, oral administration is easily destroyed and poorly absorbed. The conventional administration route of peptide drugs is injection, which has poor patient compliance. Nasal administration of peptide drugs can overcome the problems of low bioavailability of oral administration and poor compliance of injection administration, and provide a potential brain-targeted delivery route for some drugs(such as insulin). This article systematically reviewed the marketed nasal peptide preparations and analyzed their advantages in terms of administration convenience and patient compliance compared with injection dosage forms. At the same time, it reviewed the peptide nasal preparations in clinical and preclinical research and discussed strategies to improve the delivery efficiency of peptide drugs.

peptide drug  /  nasal administration  /  marketed situation  /  clinical research  /  delivery efficiency
姜艳平, 吴闻哲. 多肽类药物经鼻递送的研究进展. 世界临床药物, 2025 , 46 (12) : 1298 -1306 . DOI: 10.13683/j.wph.2025.12.015
Yanping JIANG, Wenzhe WU. Progress on nasal administration formulations of peptide drugs[J]. World Clinical Drug, 2025 , 46 (12) : 1298 -1306 . DOI: 10.13683/j.wph.2025.12.015

参考文献 引证文献
排序方式:
[1]
MUTTENTHALER M, KING GF, ADAMS DJ, et al. Trends in peptide drug discovery[J]. Nat Rev Drug Discov, 2021,20(4): 309-325.
[2]
FORBES J, KRISHNAMURTHY K. Biochemistry,peptide[M]. Treasure Island: StatPearls, 2024.
[3]
MYSKOVA A, SYKORA D, KUNES J, et al. Lipidization as a tool toward peptide therapeutics[J]. Drug Deliv, 2023,30(1): 2284685.
[4]
胡筱芸, 岳霄, 吴传斌, 等. 鼻腔药物递送的影响因素和提高递送效率的设计策略[J]. 浙江大学学报(医学版), 2023,52(3): 328-337.
[5]
LAFFLEUR F, BAUER B. Progress in nasal drug delivery systems[J]. Int J Pharm, 2021, 607: 120994.
[6]
Food and Drug Administration. DDAVP(desmopressin-acetate) nasal spray[EB/OL]. (2018-10-22)[2024-08-22].https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/017922s046lbl.pdf.
[7]
JOUKHADAR C, SCHENK B, KAEHLER ST, et al. A replicate study design for testing bioequivalence: a case study on two desmopressin nasal spray preparations[J]. Eur J Clin Pharmacol, 2003, 59(8-9): 631-636.
[8]
FEIN S. Safe desmopressin administration: US,11419914B2[P]. 2022-08-23.
[9]
ANDERSSON KE, LONGSTRETH J, BRUCKER BM, et al. Pharmacokinetic and pharmacodynamic properties of a micro-dose nasal spray formulation of desmopressin(AV002)in healthy water-loaded subjects[J]. Pharm Res, 2019, 36(6):92.
[10]
FRANSEN N, BREDENBERG S, BJORK E. Clinical study shows improved absorption of desmopressin with novel formulation[J]. Pharm Res, 2009, 26(7): 1618-1625.
[11]
FAKHR MS, KARIMI F, REZVANFAR K, et al. Comparison of the effects of vitamin D and nasal calcitonin spray with nasal calcitonin spray on postoperative abdominal pain: a randomised controlled trial[J]. Int J Surg Open, 2023, 59:100687.
[12]
HOYER H, PERERA G, BERNKOP-SCHNURCH A.Noninvasive delivery systems for peptides and proteins in osteoporosis therapy: a retroperspective[J]. Drug Dev Ind Pharm, 2010, 36(1): 31-44.
[13]
KANIS JA, BURLET N, COOPER C, et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women[J]. Osteoporos Int, 2008, 19(4):399-428.
[14]
SANDOVAL DA, D'ALESSIO DA. Physiology of proglucagon peptides: role of glucagon and GLP-1 in health and disease[J]. Physiol Rev, 2015, 95(2): 513-548.
[15]
KUMAR S, SANAP SN, PANDEY P, et al. Glucagon:Delivery advancements for hypoglycemia management[J].Int J Pharm, 2024, 652: 123785.
[16]
MANTRIPRAGADA S, PICHE C A, FILIP J J, et al. Nasal powder formulation for treatment of hypoglycemia: US,10213487B2[P]. 2019-02-26.
[17]
NGUYEN LH, JR WHITE JR. Nasal glucagon: a promising new way to treat severe hypoglycemia[J]. Clin Diabetes,2019, 37(3): 292-293.
[18]
GIMENEZ M, KHUNTI K, MATSUHISA M, et al.Systematic literature review and indirect treatment comparison of three ready-to-use glucagon treatments for severe hypoglycemia[J]. Diabetes Ther, 2023, 14(11): 1757-1769.
[19]
TANAKA A, FURUBAYASHI T, ARAI M, et al. Delivery of oxytocin to the brain for the treatment of autism spectrum disorder by nasal application[J]. Mol Pharm, 2018, 15(3):1105-1111.
[20]
BHARGAVA R, DAUGHTERS KL, REES A. Oxytocin therapy in hypopituitarism: challenges and opportunities[J].Clin Endocrinol(Oxf), 2019, 90(2): 257-264.
[21]
GOSSEN A, HAHN A, WESTPHAL L, et al. Oxytocin plasma concentrations after single intranasal oxytocin administration - a study in healthy men[J]. Neuropeptides,2012, 46(5): 211-215.
[22]
FORTUNA A, ALVES G, SERRALHEIRO A, et al.Intranasal delivery of systemic-acting drugs: small-molecules and biomacromolecules[J]. Eur J Pharm Biopharm, 2014,88(1): 8-27.
[23]
Health Canada. SUPREFACT® buserelin acetate[EB/OL]. (2020-06-02)[2024-08-22]. https://pdf.hres.ca/dpd_pm/00056627.PDF.
[24]
Food and Drug Administration. Synarel®(nafarelin acetate) nasal solution[EB/OL]. (2023-01-31)[2024-08-22]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/019886s039lbl.pdf.
[25]
BROGDEN RN, BUCKLEY MM, WARD A. Buserelin.A review of its pharmacodynamic and pharmacokinetic properties, and clinical profile[J]. Drugs, 1990, 39(3): 399-437.
[26]
FALKSON CI, FALKSON G, FALKSON HC. Long term follow-up of patients with advanced prostatic cancer treated with nasal buserelin[J]. Ann Oncol, 1991, 2(4): 303-304.
[27]
LEE D, MINKO T. Nanotherapeutics for nose-to-brain drug delivery: an approach to bypass the blood brain barrier[J].Pharmaceutics, 2021, 13(12): 2049.
[28]
PATHARAPANKAL EJ, AJIBOYE AL, MATTERN C, et al. Nose-to-brain(N2B) delivery: an alternative route for the delivery of biologics in the management and treatment of central nervous system disorders[J]. Pharmaceutics, 2023,16(1): 66.
[29]
马琳莎, 贾国舒, 周一萌, 等. 鼻用生物制品的进展与挑战[J]. 中国现代应用药学, 2023, 40(20): 2802-2810.
[30]
王晟蕾, 李凤珍, 李腾飞, 等. 胰岛素鼻腔给药治疗阿尔茨海默病研究进展[J]. 海军军医大学学报, 2024, 45(3): 333-339.
[31]
BENDICHO-LAVILLA C, SEOANE-VIANO I, OTERO-ESPINAR FJ, et al. Fighting type 2 diabetes: formulation strategies for peptide-based therapeutics[J]. Acta Pharm Sin B, 2022, 12(2): 621-636.
[32]
RABINOWICZ AL, CARRAZANA E, MAGGIO ET.Improvement of intranasal drug delivery with Intravail®alkylsaccharide excipient as a mucosal absorption enhancer aiding in the treatment of conditions of the central nervous system[J]. Drugs R D, 2021, 21(4): 361-369.
[33]
LOCHHEAD JJ, THORNE RG. Intranasal delivery of biologics to the central nervous system[J]. Adv Drug Deliv Rev, 2012, 64(7): 614-628.
[34]
NEDELCOVYCH MT, GADIANO AJ, WU Y, et al.Pharmacokinetics of intranasal versus subcutaneous insulin in the mouse[J]. ACS Chem Neurosci, 2018, 9(4): 809-816.
[35]
LI Y, HE J, LYU X, et al. Chitosan-based thermosensitive hydrogel for nasal delivery of exenatide: effect of magnesium chloride[J]. Int J Pharm, 2018, 553(1-2): 375-385.
[36]
MILEWSKI M, GOODEY A, LEE D, et al. Rapid absorption of dry-powder intranasal oxytocin[J]. Pharm Res, 2016,33(8): 1936-1944.
[37]
DAS A, VARTAK R, ISLAM MA, et al. Arginine-coated nanoglobules for the nasal delivery of insulin[J].Pharmaceutics, 2023, 15(2): 353.
[38]
GHADIRI M, YOUNG PM, TRAINI D. Strategies to enhance drug absorption via nasal and pulmonary routes[J].Pharmaceutics, 2019, 11(3):113.
[39]
MATSUYAMA T, MORITA T, HORIKIRI Y, et al.Enhancement of nasal absorption of large molecular weight compounds by combination of mucolytic agent and nonionic surfactant[J]. J Control Release, 2006, 110(2): 347-352.
[40]
WILLIAMS AJ, JORDAN F, KING G, et al. In vitro and preclinical assessment of an intranasal spray formulation of parathyroid hormone PTH 1-34 for the treatment of osteoporosis[J]. Int J Pharm, 2018, 535(1-2): 113-119.
[41]
方笑语, 葛渊源. FDA已批准鼻用制剂的辅料分析及研究进展[J]. 中国现代应用药学, 2023, 40(20): 2811-2817.
[42]
CALMET H, INTHAVONG K, EGUZKITZA B, et al. Nasal sprayed particle deposition in a human nasal cavity under different inhalation conditions[J]. PLoS One, 2019, 14(9):e0221330.
[43]
BOYUKLIEVA R, PILICHEVA B. Micro- and nanosized carriers for nose-to-brain drug delivery in neurodegenerative disorders[J]. Biomedicines, 2022, 10(7): 1706.
[44]
LAPIDOT T, BOUHAJIB M, FAULKNOR J, et al. A novel faster-acting, dry powder-based, naloxone intranasal formulation for opioid overdose[J]. Pharm Res, 2022,390(5): 963-975.
[45]
GAO M, SHEN X, MAO S. Factors influencing drug deposition in the nasal cavity upon delivery via nasal sprays[J]. J Pharm Invest, 2020, 50(3): 251-259.
[46]
TIOZZO FASIOLO L, MANNIELLO MD, TRATTA E,et al. Opportunity and challenges of nasal powders: Drug formulation and delivery[J]. Eur J Pharm Sci, 2018, 113:2-17.
[47]
DJUPESLAND PG. Nasal drug delivery devices:characteristics and performance in a clinical perspective - a review[J]. Drug Deliv Transl Res, 2013, 3(1): 42-62.
[48]
GANGER S, SCHINDOWSKI K. Tailoring formulations for intranasal nose-to-brain delivery: a review on architecture,physico-chemical characteristics and mucociliary clearance of the nasal olfactory mucosa[J]. Pharmaceutics, 2018, 10(3):116.
[49]
DESAI MM, PATIL PD, JADHAV SA, et al. Recent advancements in nasal drug delivery devices[J]. Int J Drug Deliv Technol, 2024, 14(4): 619-624.
2025年第46卷第12期
50
9
0
引用本文
BibTeX
文章信息
doi: 10.13683/j.wph.2025.12.015
  • 接收时间:2025-07-05
  • 首发时间:2026-11-09
  • 出版时间:2025-12-10
补充材料
相关文章
文章信息
作者
出版历史
  • 收稿日期:2025-07-05
基金
作者信息
    中国医药工业研究总院医药先进制造国家工程研究中心,上海 201203

通讯作者:

吴闻哲,研究员,硕士生导师,从事经鼻及吸入给药研究。
参考文献
分享链接
https://castjournals.cast.org.cn/joweb/sjlcyw/CN/10.13683/j.wph.2025.12.015
分享至
全文二维码

扫描看全文

引用本文
BibTeX
本文的引用情况
2种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏